Ruxolitinib

DESCRIPTION

Ruxolitinib is a potent Janus-associated Kinase (JAK1 IC50 2.7nM, JAK2 IC50 4.5nM) inhibitor. JAK1 and JAK2 transduce cytokine-mediated signals and are involved in interferon-gamma signaling. Ruxolitinib is reported to block IL-6 signaling and inhibits the proliferation of erythroid progenitors. It is currently being researched as a potential treatment for COVID-19.

DETAILS

Purity: ≥98%
Synonyms: INCB018424, Jakavi, Jakafi, INCB-018424
Cas Number: 941678-49-5
References: Mesa, R. A. (2010). Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. IDrugs: the investigational drugs journal, 13(6), 394-403. Heine, A., Held, S. A. E., Daecke, S. N., Wallner, S., Yajnanarayana, S. P., Kurts, C., ... & Brossart, P. (2013). The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, 122(7), 1192-1202. Shi, J. G., Chen, X., McGee, R. F., Landman, R. R., Emm, T., Lo, Y., ... & Yeleswaram, S. (2011). The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. The Journal of Clinical Pharmacology, 51(12), 1644-1654.
Application: FA
Formulation: Crystalline solid
Chemical Name: (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
Molecular Weight: 306.4
Molecular Formula: C17H18N6
Storage Conditions: Product should be kept at -20°C.
Pubchem Openeye Can Smiles: C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3